Clinical Trial

DK222 Study at Hopkins

Recruiting Phase 1

Summary

This Phase 1 clinical trial will test a new drug called \[18F\]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. \[18F\]DK222 is designed to attach strongly and specifically to a protein called PD-L1, which helps cancer hide from the immune system. This is a first in human study to collect preliminary safety and toxicity data of \[18F\]DK222.

Protocol Amendment History 5 changes

notable Primary completion pushed: 2027-07-01 -> 2027-09-01 2026-07-29

minor Completion pushed: 2027-07-01 -> 2027-09-01 2026-07-29

notable Primary completion pushed: 2027-05-01 -> 2027-07-01 2026-05-23

minor Completion pushed: 2027-05-01 -> 2027-07-01 2026-05-23

critical Recruitment opened 2026-04-03

Trial Details

NCT Number	NCT07140315
Lead Sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions	Non-Small Cell Lung Cancer, Urothelial Cancer
Enrollment	6 participants
Start Date	2026-09-01
Primary Completion	2027-09-01 (estimated)
Study Completion	2027-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-28